2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 42(2008) N 5 p. 687-698;
E.N. Imyanitov

Molecular diagnosis in oncology

Petrov Institute of Oncology, St. Petersburg, 197758, Russia
Received - 2008-04-01; Accepted - 2008-04-01

Recent advances of molecular genetics have exerted a noticeable effect on some areas of clinical medicine. A comprehensive understanding of the nature of hereditary tumors is frequently heralded as the most substantial practical achievement of molecular oncology. Proper diagnostic algorithms have already been developed for the vast majority of known familial cancer syndromes. Interestingly, an unexpectedly strong founder effect has been documented at least for some hereditary cancers occurring in Russia, which significantly simplifies the detection of the corresponding disease-associated gene variants. The number of tests aimed at customizing cancer treatment continues to grow every year. The EGFR mutation test is probably the most impressive one, as it predicts the lung cancer response or nonresponse to gefitinib or erlotinib with a really unprecedented accuracy. Approaches helping to determine the individual efficacy and safety profiles for fluoropyrimidines, platinum compounds, irinotecan, etc. are currently under development. Methods detecting residual amounts of disseminated cancer cells represent another popular avenue of research. These technologies are expected to improve the quality of prediction of local and distant metastases, facilitate monitoring of the minimal residual disease, and, in the long-term perspective, provide a tool for early cancer diagnosis. It should be emphasized that molecular detection of disseminated tumor cells is currently used mainly in research settings and is not yet incorporated into routine clinical practice.

Cancer, hereditary cancer syndromes, predictive markers, disseminated tumor cells, molecular diagnosis